GX-G8 / Genexine - LARVOL DELTA

Genexine voluntarily suspends phase 1 clinical trial for short bowel syndrome treatment ‘GX-G8’ [Google translation] (Pharm News) - "Genexine announced...that it decided to voluntarily suspend the phase 1 clinical trial of 'GX-G8' (short bowel syndrome treatment). Regarding the voluntary discontinuation of the clinical trial, the company explained, "Short bowel syndrome is a very rare disease whose exact prevalence is not known, and the number of patients is very small, making it difficult to recruit patients both domestically and overseas, so we decided to voluntarily discontinue the clinical trial as a strategic management decision."

Trial suspension • Gastroenterology • Short Bowel Syndrome